ArticleBrain & spine2026
Clinical outcomes and survival benefits of craniotomy in breast cancer patients with brain metastases: Focusing on candidate selection and early mortality.
Article in Brain & spine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Surgical decision-making for breast cancer (BC) brain metastases (BM) remains challenging due to surgery-related mortality risk. This study evaluated survival benefits of craniotomy and investigated causes of early postoperative mortality to refine surgical candidate selection. Methods: This retrospective cohort study included 157 BC patients with BM (July 2006-August 2022). Demographics, cancer subtype, performance score, BM number, extracranial metastasis, and treatment details were collected. Survival was analyzed using Kaplan-Meier and Cox regression models. Propensity score matching (PSM) was applied to control for confounding. A subgroup analysis of "short survivors" (survival <6 months) investigated early mortality causes. Results: The mean age was 52.4 years; 36.9% had triple-negative breast cancer and 21.7% were HER2-positive. Craniotomy was performed in 37.4% of patients and was associated with improved overall survival (30-month survival rate: 30%, p < 0.001). Multivariate analysis identified oligometastases (p < 0.001), multiple metastases (p = 0.007), and absence of radiotherapy exposure (p = 0.005) as independent predictors of poor prognosis. Among 16 short-term survivors (<6 months), only three (18.8%) died within 30 days due to surgery-related complications; the remainder died from systemic disease progression. Conclusions: While craniotomy was associated with improved overall survival in the unadjusted analysis, this association was attenuated after PSM, suggesting patient selection may substantially account for the observed difference. Single brain metastasis and radiotherapy exposure were significant independent predictors of survival. Short-term survivor analysis revealed two distinct mortality patterns: the majority died from disease progression, while three patients experienced surgery-related death within 30 days. Rigorous patient selection remains essential in surgical decision-making.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.